Az inzulinszekretagóg antidiabetikumok farmakogenetikai vonatkozásai

Translated title of the contribution: Pharmacogenetics of insulin secretagogue antidiabetics

G. Winkler, László Gero

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Type 2 diabetes is making up to 90% of the all diabetic cases. In addition to insulin resistance, insufficient B-cell function also plays an important role in the pathogenesis of the disease. The insufficient production and secretion of insulin can be increased by secretagogue drugs, like sulfonylureas and incretin mimetics/enhancers. In recent years growing number of genetic failures of the B-cells has been detected. These genetic variants can influence the efficacy of secretagogue drugs. Some of these gene polymorphisms were identified in the genes encoding the KATP channel (KCNJ11 and ABCC8). These mutations are able either to reduce or increase the insulin secretion and can modify the insulin response to sulfonylurea treatment. Other polymorphisms were found on genes encoding enzymes or transcription factors. In the recent years the genetic variants of TCF7L2 and its clinical importance have been intensively studied. Authors give a summary of the above gene polymorphisms and their role in the insulin secretion. Orv. Hetil., 2011, 152, 1651-1660.

Original languageHungarian
Pages (from-to)1651-1660
Number of pages10
JournalOrvosi Hetilap
Volume152
Issue number41
DOIs
Publication statusPublished - Oct 1 2011

Fingerprint

Pharmacogenetics
Hypoglycemic Agents
Insulin
Genes
B-Lymphocytes
Incretins
KATP Channels
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Insulin Resistance
Transcription Factors
Mutation
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az inzulinszekretagóg antidiabetikumok farmakogenetikai vonatkozásai. / Winkler, G.; Gero, László.

In: Orvosi Hetilap, Vol. 152, No. 41, 01.10.2011, p. 1651-1660.

Research output: Contribution to journalArticle

Winkler, G. ; Gero, László. / Az inzulinszekretagóg antidiabetikumok farmakogenetikai vonatkozásai. In: Orvosi Hetilap. 2011 ; Vol. 152, No. 41. pp. 1651-1660.
@article{b562671052e14d38b723e8c15f38b096,
title = "Az inzulinszekretag{\'o}g antidiabetikumok farmakogenetikai vonatkoz{\'a}sai",
abstract = "Type 2 diabetes is making up to 90{\%} of the all diabetic cases. In addition to insulin resistance, insufficient B-cell function also plays an important role in the pathogenesis of the disease. The insufficient production and secretion of insulin can be increased by secretagogue drugs, like sulfonylureas and incretin mimetics/enhancers. In recent years growing number of genetic failures of the B-cells has been detected. These genetic variants can influence the efficacy of secretagogue drugs. Some of these gene polymorphisms were identified in the genes encoding the KATP channel (KCNJ11 and ABCC8). These mutations are able either to reduce or increase the insulin secretion and can modify the insulin response to sulfonylurea treatment. Other polymorphisms were found on genes encoding enzymes or transcription factors. In the recent years the genetic variants of TCF7L2 and its clinical importance have been intensively studied. Authors give a summary of the above gene polymorphisms and their role in the insulin secretion. Orv. Hetil., 2011, 152, 1651-1660.",
keywords = "glucagon-like peptide-1, incretins, insulin secretion, neonatal diabetes, pharmacogenetics, sulfonylurea, type 2 diabetes",
author = "G. Winkler and L{\'a}szl{\'o} Gero",
year = "2011",
month = "10",
day = "1",
doi = "10.1556/OH.2011.29175",
language = "Hungarian",
volume = "152",
pages = "1651--1660",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "41",

}

TY - JOUR

T1 - Az inzulinszekretagóg antidiabetikumok farmakogenetikai vonatkozásai

AU - Winkler, G.

AU - Gero, László

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Type 2 diabetes is making up to 90% of the all diabetic cases. In addition to insulin resistance, insufficient B-cell function also plays an important role in the pathogenesis of the disease. The insufficient production and secretion of insulin can be increased by secretagogue drugs, like sulfonylureas and incretin mimetics/enhancers. In recent years growing number of genetic failures of the B-cells has been detected. These genetic variants can influence the efficacy of secretagogue drugs. Some of these gene polymorphisms were identified in the genes encoding the KATP channel (KCNJ11 and ABCC8). These mutations are able either to reduce or increase the insulin secretion and can modify the insulin response to sulfonylurea treatment. Other polymorphisms were found on genes encoding enzymes or transcription factors. In the recent years the genetic variants of TCF7L2 and its clinical importance have been intensively studied. Authors give a summary of the above gene polymorphisms and their role in the insulin secretion. Orv. Hetil., 2011, 152, 1651-1660.

AB - Type 2 diabetes is making up to 90% of the all diabetic cases. In addition to insulin resistance, insufficient B-cell function also plays an important role in the pathogenesis of the disease. The insufficient production and secretion of insulin can be increased by secretagogue drugs, like sulfonylureas and incretin mimetics/enhancers. In recent years growing number of genetic failures of the B-cells has been detected. These genetic variants can influence the efficacy of secretagogue drugs. Some of these gene polymorphisms were identified in the genes encoding the KATP channel (KCNJ11 and ABCC8). These mutations are able either to reduce or increase the insulin secretion and can modify the insulin response to sulfonylurea treatment. Other polymorphisms were found on genes encoding enzymes or transcription factors. In the recent years the genetic variants of TCF7L2 and its clinical importance have been intensively studied. Authors give a summary of the above gene polymorphisms and their role in the insulin secretion. Orv. Hetil., 2011, 152, 1651-1660.

KW - glucagon-like peptide-1

KW - incretins

KW - insulin secretion

KW - neonatal diabetes

KW - pharmacogenetics

KW - sulfonylurea

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=80053551428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053551428&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29175

DO - 10.1556/OH.2011.29175

M3 - Article

C2 - 21959939

AN - SCOPUS:80053551428

VL - 152

SP - 1651

EP - 1660

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 41

ER -